| LOOKING AHEAD |
|
| Over the last few years, we have been moving towards a profile that is much more international and formulation-driven. |
|
| The Sun Pharma of tomorrow will have brands registered in major markets of the world, and in most markets, promoted by a high quality field force. In India, we expect to retain our position of market leadership in our key therapy areas, and reach leadership in newer therapy areas that we entered after 1997. In key international markets across Asia, South East Asia, Russia, China, the Middle East, Latam and Africa we would be a strong speciality company with prescription driven sales. With a strong network and established company equity, we would be an excellent partner for a company seeking to license out products across markets. |
|
| In the high value generic markets of the US we expect to become a respected generic company, with a portfolio comprising both of complex and simple-to-file generics, building an edge with technology and the cost advantage of vertical integration. While we have recently completed our fourth acquisition in the US, we believe there are excellent opportunities in the US generic space, where we can affect a turnaround and add value to a business. We have about $400 million earmarked for acquisitions in the US generic/drug discovery space. |
|
| Our innovation-based R&D programs were recently demerged into a separate company. The new R&D company will have projects covering new molecule and novel drug delivery in late phase human trials over the next few years, which it may seek to license out. |
|
 |
|
|
|
|
|
|
|
News Articles
Contact Us
